blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP1033988

EP1033988 - PARENTERAL FORMULATIONS COMPRISING 10-HYDROXY-10,11-TETRAHYDROCARBAMAZEPINE, WATER AND GLUCOSE [Right-click to bookmark this link]
Former [2000/37]PARENTERAL FORMULATIONS COMPRISING CARBAMAZEPINE OR ITS DERIVATIVES
[2003/20]
StatusNo opposition filed within time limit
Status updated on  12.11.2004
Database last updated on 20.07.2024
Most recent event   Tooltip12.11.2004No opposition filed within time limitpublished on 29.12.2004  [2004/53]
Applicant(s)For:BE  CH  DE  DK  ES  FI  FR  GB  GR  IE  IT  LU  NL  PT  SE  CY  LI 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1230 Wien / AT
[N/P]
Former [2003/11]For:BE  CH  DE  DK  ES  FI  FR  GB  GR  IE  IT  LU  NL  PT  SE  CY  LI 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1230 Wien / AT
Former [2003/10]For:BE  CH  DE  DK  ES  FI  FR  GB  GR  IE  IT  LU  NL  PT  SE  CY  LI 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis Pharma GmbH
Brunner Strasse 59
1235 Vienna / AT
Former [2001/32]For:BE  CH  DE  DK  ES  FI  FR  GB  GR  IE  IT  LU  NL  PT  SE  CY  LI 
Novartis AG
Lichtstrasse 35
4056 Basel / CH
For:AT 
Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
Brunnerstrasse 59
1230 Wien / AT
Former [2000/37]For:BE  CH  DE  DK  ES  FI  FR  GB  GR  IE  IT  LU  NL  PT  SE  CY  LI 
Novartis AG
Schwarzwaldallee 215
4058 Basel / CH
For:AT 
Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
Brunnerstrasse 59
1230 Wien / AT
Inventor(s)01 / VAN HOOGEVEST, Peter
Breitenstrasse 3
CH-4416 Bubendorf / CH
[2000/37]
Representative(s)Grubb, Philip William, et al
Novartis AG
Corporate Intellectual Property
Lichtstrasse 35
4002 Basel / CH
[N/P]
Former [2003/20]Grubb, Philip William, et al
Novartis AG, Corporate Intellectual Property, Lichtstrasse 35
4002 Basel / CH
Former [2000/37]Becker, Konrad, et al
Novartis AG Geistiges Eigentum Konzern Patent- und Markenabteilung CH Postfach
4002 Basel / CH
Application number, filing date98950110.107.10.1998
[2000/37]
WO1998EP06382
Priority number, dateGB1997002149709.10.1997         Original published format: GB 9721497
[2000/37]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9918966
Date:22.04.1999
Language:EN
[1999/16]
Type: A1 Application with search report 
No.:EP1033988
Date:13.09.2000
Language:EN
The application published by WIPO in one of the EPO official languages on 22.04.1999 takes the place of the publication of the European patent application.
[2000/37]
Type: B1 Patent specification 
No.:EP1033988
Date:07.01.2004
Language:EN
[2004/02]
Search report(s)International search report - published on:EP22.04.1999
ClassificationIPC:A61K31/55, A61P25/08
[2003/20]
CPC:
A61K31/55 (EP,KR,US); A61P21/02 (EP); A61P25/00 (EP);
A61P25/08 (EP)
Former IPC [2000/37]A61K31/55
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   NL,   PT,   SE [2000/37]
Extension statesRO08.03.2000
SI08.03.2000
TitleGerman:PARENTERALE ZUBEREITUNGEN ENTHALTEND 10-HYDROXY-10,11-TETRAHYDROCARBAMAZEPINE, WASSER UND GLUKOSE[2003/22]
English:PARENTERAL FORMULATIONS COMPRISING 10-HYDROXY-10,11-TETRAHYDROCARBAMAZEPINE, WATER AND GLUCOSE[2003/20]
French:FORMULATIONS PARENTERALES CONTENANT DE LA 10-HYDROXY-10,11-TETRAHYDROCARBAMAZEPINE, DE L'EAU ET DU GLUCOSE[2003/20]
Former [2000/37]PARENTERAL ZUBEREITUNGEN ENTHALTEND CARBAMAZEPINE ODER DERIVATE DAVON
Former [2000/37]PARENTERAL FORMULATIONS COMPRISING CARBAMAZEPINE OR ITS DERIVATIVES
Former [2000/37]FORMULATIONS PARENTERALES CONTENANT DE LA CARBAMAZEPINE OU DES DERIVES DE CETTE DERNIERE
Entry into regional phase08.03.2000National basic fee paid 
08.03.2000Designation fee(s) paid 
08.03.2000Examination fee paid 
Examination procedure14.04.1999Request for preliminary examination filed
International Preliminary Examining Authority: EP
08.03.2000Examination requested  [2000/37]
01.07.2002Despatch of a communication from the examining division (Time limit: M06)
30.12.2002Reply to a communication from the examining division
07.05.2003Communication of intention to grant the patent
17.09.2003Fee for grant paid
17.09.2003Fee for publishing/printing paid
Opposition(s)08.10.2004No opposition filed within time limit [2004/53]
Fees paidRenewal fee
24.08.2000Renewal fee patent year 03
12.09.2001Renewal fee patent year 04
31.10.2002Renewal fee patent year 05
31.10.2003Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XY]EP0435826  (CIBA GEIGY AG [CH]) [X] 1,2,7-10 * example 1 * [Y] 1-10;
 [XY]WO9420110  (RHONE POULENC RORER SA [FR], et al) [X] 1,2,7-10 * example 3 * [Y] 1,2,7-10;
 [XY]US5466683  (STERLING JEFF [IL], et al) [X] 1,2,7-10 * column 3, lines 15-20 * * columns 3354-58; claims 15-17 * [Y] 1-10;
 [Y]  - FARAGO, "TRIGEMINAL NEURALGI: ITS TREATMENT WITH TWO NEW CARBAMAZEPINE ANALOGUES", EUROPEAN NEUROLOGY, SWITZERLAND, (1987), vol. 26, no. 2, pages 73 - 83, XP002089864 [Y] 3-6 * abstract *

DOI:   http://dx.doi.org/10.1159/000116315
 [Y]  - JAMES E. F. REYNOLDS, MARTINDALE THE EXTRA PHARMACOPOEIA, LONDON, GREAT BRITAIN, THE PHARMACEUTICAL PRESS, (1993), XP002089865 [Y] 1-10 * PAGES 295-298; esp. p. 298, left column, l. 19-21 *
 [X]  - FASS 1996 LÄKEMEDEL I SVERIGE FÖRTECKNING ÖVER HUMANLÄKEMEDEL, SWEDEN, LINFO LÄKEMEDELSINFORMATION AB, (1996), XP002089866 [X] 1,2,7-10 * Page 992: Tegretol mixtur *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.